nach oben

Annals of Hematology

Erschienen in:

01.03.2012 | Original Article

The time-dependent autophagy protects against apoptosis with possible involvement of Sirt1 protein in multiple myeloma under nutrient depletion

verfasst von: Rong Zeng, Jing He, Jin Peng, Yan Chen, Sha Yi, Fei Zhao, Guohui Cui

Erschienen in: Annals of Hematology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The absence of researches about autophagy in multiple myeloma promoted us to explore the biological characteristics and role of autophagy induced by nutrient depletion in multiple myeloma (MM) cell line RPMI8226 cells. Both autophagic and apoptotic morphology were observed by TUNEL, transmission electron microscopy (TEM), and monodansylcadervarine (MDC) staining. MDC staining fluorescent intensity and the conversion of LC3-I to LC3-II demonstrated autophagy increased time-dependently at 6, 12, and 18 h then declined at 24 and 48 h. FCM analysis of Annexin V-FITC/PI (AV/PI) dual staining and TUNEL assay demonstrated apoptosis increased time-dependently at 6, 12, 18, 24, and 48 h, and it burst at 24 h when autophagy declined. Bax translocation from cytoplasm to mitochondria and active caspase3 protein level were promoted time dependently along with the increase of apoptosis. We demonstrated the same time-course pattern of Beclin1 protein and mRNA level as autophagy. The phosphorylating rate of S6K1 was inhibited at 6, 12, and 18 h when autophagy increased. Inhibition of autophagy by 3-methyladenine (3-MA) facilitated apoptosis and caspase3 activation at 6, 12, and 18 h but made no effect at 24 or 48 h. Sirt1 protein level in nuclei was gradually enhanced along with the increase of autophagy, however, 3-MA suppressed this enhancement. Taken together, nutrient depletion induced the time-dependent autophagy and apoptosis. Apoptosis was demonstrated as caspase3-mediated and Bax-dependent mitochondrial apoptosis. Autophagy appears to be Beclin1-dependent and related to mTORC1 inhibition. Autophagy protected against the apoptosis in the early period. Sirt1 possibly contributed to autophagy and was involved in pro-survival process mediated by autophagy.

Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7:961–967. doi:10.1038/nrc2254 PubMedCrossRef

Amaravadi RK, Thompson CB (2007) The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13:7271–7279. doi:10.1158/1078-0432 PubMedCrossRef

Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5:726–734. doi:10.1038/nrc1692 PubMedCrossRef

Shintani T, Klionsky DJ (2004) Autophagy in health and disease: a double-edged sword. Science 306:990–995. doi:10.1126/science.1099993 PubMedCrossRef

Yoshinori T, Domenico C, Norimasa M et al (2007) Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 9(10):1142–1151. doi:10.1038/ncb1634 CrossRef

Codogno P, Meijer AJ (2005) Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 12:1509–1518. doi:10.1038/sj.cdd.4401751 PubMedCrossRef

Liang XH, Jackson S, Seaman M et al (1999) Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature 420:672–676. doi:10.1038/45257

Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23:2891–2906. doi:10.1038/sj.onc.1207521 PubMedCrossRef

Lum JJ, Bauer DE, Kong M et al (2005) Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120:237–248. doi:10.1016/j.cell.2004.11.046 PubMedCrossRef

10.

Yu L, Wan F, Dutta S, Welsh S et al (2006) Autophagic programmed cell death by selective catalase degradation. Pro Natl Acad Sci USA 103:4952–4957. doi:10.1073/pnas.0511288103 CrossRef

11.

Tsujimoto Y, Shimizu S (2005) Another way to die: autophagic programmed cell death. Cell Death Differ 12:1528–1534. doi:10.1038/sj.cdd.4401777 PubMedCrossRef

12.

Bursch W, Ellinger A, Gerner C et al (2000) Programmed cell death(PCD): Apoptosis, autophagic PCD, or others? Ann NY Acad Sci 926:1–12. doi:10.1111/j.1749-6632.2000.tb05594 PubMedCrossRef

13.

Gosselin K, Deruy E, Martien S et al (2009) Senescent keratinocytes die by autophagic programmed cell death. Am J Pathol 174:423–435. doi:10.2353/ajpath.2009.080332 PubMedCrossRef

14.

Kanzawa T, Zhang L, Xiao L et al (2005) Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene 24:980–991. doi:10.1038/sj.onc.1208095 PubMedCrossRef

15.

Kanzawa T, Germano IM, Komata T et al (2004) Role of autophagy in temozolomide-induced cytotoxicity for maglinant glioma cells. Cell Death Differ 11:448–457. doi:10.1038/sj.cdd.4401359 PubMedCrossRef

16.

Kourtis N, Tavernarakis N (2009) Autophagy and cell death in model organisms. Cell Death Differ 16:21–30. doi:10.1038/cdd.2008.120 PubMedCrossRef

17.

Yoshimori T (2004) Autophagy: a regulated bulk degradation process inside cells. Biochem Biophys Res Commun 313:453–458. doi:10.1016/j.bbrc.2003.07.023 PubMedCrossRef

18.

Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463–477. doi:10.1016/S1534-5807(04)00099-1 PubMedCrossRef

19.

Klionsky DJ (2007) Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 8:931–937. doi:10.1038/nrm2245 PubMedCrossRef

20.

Pattingre S, Tassa A, Qu X et al (2005) Bcl-2 anti-apoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122:927–939. doi:10.1016/j.cell.2005.07.002 PubMedCrossRef

21.

Noboru M (2007) Autophagy: process and function. Genes Dev 21:2861–2873. doi:10.1101/gad.1599207 CrossRef

22.

Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P (2007) Regulation of macroautophagy by mTOR and Beclin 1 complex. Biochimie 10:1016–1026. doi:10.1016/j.biochi.2007.08.014

23.

Noda T, Ohsumi Y (1998) Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem 273:3963–3966. doi:10.1074/jbc.273.7.3963 PubMedCrossRef

24.

Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484. doi:10.1016/j.cell.2006.01.016 PubMedCrossRef

25.

Hara K, Yonezawa K, Weng QP et al (1998) Amino acid sufficiency and mTOR regulates p70 S6 kinase and eIF-4EBP1 through a common effector mechanism. J Biol Chem 273:14484–14494. doi:10.1074/jbc.273.23.14484 PubMedCrossRef

26.

Kim EJ, Um SJ (2008) SIRT1: roles in aging and cancer. BMB Rep 10:751–756CrossRef

27.

Liu T, Liu PY, Marshall GM (2009) The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 69(5):1702–1705. doi:10.1158/0008-5472.CAN-08-3365 PubMedCrossRef

28.

Haigis MC, Guarente LP (2006) Mammalian sirtuins-emerging roles in physiology, aging and calorie restriction. Genes Dev 20:2913–2921. doi:10.1101/gad.1467506 PubMedCrossRef

29.

Deng CX (2009) SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 5(2):147–152PubMedCrossRef

30.

Chung S, Yao H, Caito S et al (2010) Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 501:79–90. doi:10.1016/j.abb.2010.05.003 PubMedCrossRef

31.

Kojima K, Ohhashi R, Fujita Y et al (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373:423–428. doi:10.1016/j.bbrc.2008.06.045 PubMedCrossRef

32.

Annette B, Horst FK, Hans PE (1995) Monodansylcadaverine(MDC) is specific in vivo marker for autophagic vacuoles. Eur J Cell Biol 66:3–14

33.

Scott RC, Schuldiner O, Neufeld TP (2004) Role and regulation of starvation-induced autophagyin the Drosophila fat body. Dev Cell 7:167–178. doi:10.1016/j.devcel.2004.07.009 PubMedCrossRef

34.

Zhu JH, Horbinski C, Guo F et al (2007) Regulation of autophagy by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. Am J Pathol 170:75–86. doi:10.2353/ajpath.2007.060524 PubMedCrossRef

35.

Kim I, Rodriguez-Enriquez S, Lemasters JJ (2007) Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 462:245–253. doi:10.1016/j.abb.2007.03.034 PubMedCrossRef

36.

Mordier S, Deval C, Bechet D et al (2000) Leucine limitation induces autophagy and activation of lysosome-dependent proteolysis in C2C12 myotubes through a mammalian target of rapamycin-independent signaling pathway. J Biol Chem 275:29900–29906. doi:10.1074/jbc.M003633200 PubMedCrossRef

37.

Kanazawa T, Taneike I, Akaishi R et al (2004) Amino acids and insulin control autophagic proteolysis through different signaling pathways in relation to mTOR in isolated rat hepatocytes. J Biol Chem 279:8452–8459. doi:10.1074/jbc.M306337200 PubMedCrossRef

38.

Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7(12):1013–1030. doi:10.1038/nrd2755 PubMedCrossRef

39.

Rasheva VI, Domingos PM (2009) Cellular responses to endoplasmic reticulum stress and apoptosis. Apoptosis 14(8):996–1007. doi:10.1007/s10495-009-0341-y PubMedCrossRef

40.

Ford J, Jiang M, Milner J (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65:10457–10463. doi:10.1158/0008-5472.CAN-05-1923 PubMedCrossRef

41.

Carew JS, Nawrocki ST, Kahue CN et al (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance. Blood 110:313–322. doi:10.1182/blood-2006-10-050260 PubMedCrossRef

Titel: The time-dependent autophagy protects against apoptosis with possible involvement of Sirt1 protein in multiple myeloma under nutrient depletion
verfasst von: Rong Zeng
Jing He
Jin Peng
Yan Chen
Sha Yi
Fei Zhao
Guohui Cui
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Annals of Hematology / Ausgabe 3/2012
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-011-1315-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The time-dependent autophagy protects against apoptosis with possible involvement of Sirt1 protein in multiple myeloma under nutrient depletion

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

AL amyloidosis with severe gastrointestinal invasion and acute obstructive suppurative cholangitis

Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast

Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials

Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan

Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders

Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin